Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy

Published:2022-02-20 Issue:3 Volume:32 Page:142-149
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Zhou Li,Yang Yue,Si Lu,Chi Zhihong,Sheng Xinan,Lian Bin,Wang Xuan,Tang Bixia,Mao Lili,Yan Xieqiao,Li Siming,Bai Xue,Guo Jun,Cui Chuanliang

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference27 articles.

1. Systemic therapy for melanoma: ASCO guideline.;Seth;J Clin Oncol,2020

2. Pembrolizumab versus ipilimumab in advanced melanoma.;Robert;N Engl J Med,2015

3. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.;Atkins;Immunotherapy,2019

4. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.;Ribas;Nat Med,2019

5. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial—ECOG-ACRIN EA6134.;Atkins;J Clin Oncol,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects;Critical Reviews in Oncology/Hematology;2024-09

2. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23

3. Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma;European Journal of Medical Research;2023-09-16

4. Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial;European Journal of Cancer;2023-03

5. Quoi de neuf en oncodermatologie ?;Annales de Dermatologie et de Vénéréologie - FMC;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3